Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Neurizon to Welcome Chris Bremer as CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Neurizon to Welcome Chris Bremer as CEO

Bremer’s appointment takes effect Oct. 1.

Author Image

By: Patrick Lavery

Content Marketing Editor

Why This Matters: See our coverage of other industry executive team appointments and promotions here.

Neurizon Therapeutics is naming Chris Bremer, MD, PhD, its Chief Executive Officer (CEO) effective Oct. 1, 2026. A clinical-stage biotechnology company, Neurizon specializes in innovating neurodegenerative disease treatments.

Currently, Neurizon is advancing its lead drug candidate, NUZ-001, through a Phase II/III trial in amyotrophic lateral sclerosis (ALS). Topline results from this trial (HEALEY ALS) are due in the second quarter of 2027.

New CEO Experience

Headlining Bremer’s experience, approximately 20 years with Grünenthal, progressively serving in senior commercial, strategic, and global leadership roles. At Grünenthal, Bremer executed on more than $1 billion in licensing transactions.

Following that period, Bremer was Chief Development Officer at Navigo Proteins. He was also the founding CEO of Gaiaso Theranostics. In his career to date, Bremer has led organizations of up to 500 employees.

“I am honored to join Neurizon at such an important point in the Company’s development,” Bremer said.

What Neurizon Has on the Horizon

Bremer added being attracted by the underlying science and advanced clinical program for NUZ-001. Additionally, he looks forward to contributing to the development of a potential new ALS treatment.

“Throughout my career, I have worked at the intersection of scientific development, portfolio strategy, commercialization, and strategic partnering,” Bremer said. “Neurizon has established important clinical, regulatory, manufacturing, and scientific progress.  I look forward to building on this work with the board and the team.”

Outside of the pharmaceutical world, Bremer represented Germany in swimming at the 1992 and 1996 Olympic Games.

Neurizon clarified, though Bremer is the incoming CEO, he will not be installed as a director of Neurizon Therapeutics Limited.

Overall, company priorities at the moment include continued regulatory and CMC readiness, and further scientific evidence surrounding NUZ-001.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics